• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    2/29/24 12:32:04 PM ET
    $AMPE
    $COCH
    $CSTL
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Health Care
    Get the next $AMPE alert in real time by email

    Gainers

    • Societal CDMO (NASDAQ:SCTL) stock rose 132.6% to $1.07 during Thursday's regular session. The company's market cap stands at $112.1 million.
    • Enveric Biosciences (NASDAQ:ENVB) shares increased by 132.25% to $1.93. The market value of their outstanding shares is at $5.2 million.
    • Envoy Medical (NASDAQ:COCH) stock rose 47.29% to $5.17. The market value of their outstanding shares is at $101.0 million.
    • Tivic Health Systems (NASDAQ:TIVC) shares moved upwards by 30.39% to $1.63. The market value of their outstanding shares is at $2.3 million.
    • Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 29.68% to $7.34. The company's market cap stands at $644.5 million. The company's, Q4 earnings came out yesterday.
    • Renalytix (NASDAQ:RNLX) shares increased by 28.91% to $1.07. The company's market cap stands at $53.4 million.

    Losers

    • Kineta (NASDAQ:KA) shares fell 42.5% to $1.3 during Thursday's regular session. The market value of their outstanding shares is at $13.5 million.
    • Ironwood Pharmaceuticals (NASDAQ:IRWD) stock fell 39.89% to $9.09. The market value of their outstanding shares is at $1.4 billion.
    • Grifols (NASDAQ:GRFS) shares declined by 27.63% to $6.76. The company's market cap stands at $4.5 billion.
    • Ampio Pharmaceuticals (AMEX:AMPE) shares fell 24.35% to $1.74. The market value of their outstanding shares is at $1.9 million.
    • Gyre Therapeutics (NASDAQ:GYRE) shares fell 22.37% to $19.25. The company's market cap stands at $1.6 billion.
    • Castle Biosciences (NASDAQ:CSTL) stock fell 20.85% to $19.3. The market value of their outstanding shares is at $519.5 million. As per the press release, Q4 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMPE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMPE
    $COCH
    $CSTL
    $ENVB

    CompanyDatePrice TargetRatingAnalyst
    Ironwood Pharmaceuticals Inc.
    $IRWD
    1/5/2026$8.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Gyre Therapeutics Inc.
    $GYRE
    10/10/2025$16.00Buy
    Jefferies
    Gyre Therapeutics Inc.
    $GYRE
    8/26/2025$18.00Buy
    H.C. Wainwright
    Ironwood Pharmaceuticals Inc.
    $IRWD
    4/15/2025Overweight → Equal Weight
    Wells Fargo
    Ironwood Pharmaceuticals Inc.
    $IRWD
    4/15/2025Buy → Hold
    Jefferies
    Ironwood Pharmaceuticals Inc.
    $IRWD
    4/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Gyre Therapeutics Inc.
    $GYRE
    3/11/2025Outperform
    Noble Capital Markets
    Grifols S.A.
    $GRFS
    2/12/2025Overweight
    Morgan Stanley
    More analyst ratings

    $AMPE
    $COCH
    $CSTL
    $ENVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres. & Chief Exec. Officer Maetzold Derek J exercised 6,226 shares at a strike of $2.39 and sold $1,132,821 worth of shares (44,125 units at $25.67), decreasing direct ownership by 32% to 71,558 units (SEC Form 4)

    4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)

    3/13/26 4:10:14 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Chief Legal Officer John Minardo was granted 136,612 shares, increasing direct ownership by 38% to 500,498 units (SEC Form 4)

    4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

    3/12/26 4:05:13 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Martini Gregory S. was granted 136,612 shares, increasing direct ownership by 85% to 297,213 units (SEC Form 4)

    4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

    3/12/26 4:05:11 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPE
    $COCH
    $CSTL
    $ENVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Interim CFO Potashnick Robert bought $85,000 worth of shares (212,500 units at $0.40) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:49:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Director Kantor Susan bought $38,460 worth of shares (96,150 units at $0.40), increasing direct ownership by 123% to 174,037 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:47:12 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $AMPE
    $COCH
    $CSTL
    $ENVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ironwood Pharma upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Ironwood Pharma from Mkt Perform to Mkt Outperform and set a new price target of $8.00

    1/5/26 8:35:09 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Gyre Therapeutics with a new price target

    Jefferies initiated coverage of Gyre Therapeutics with a rating of Buy and set a new price target of $16.00

    10/10/25 8:38:16 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Gyre Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Gyre Therapeutics with a rating of Buy and set a new price target of $18.00

    8/26/25 8:17:41 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPE
    $COCH
    $CSTL
    $ENVB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for DAXXIFY issued to REVANCE THERAPEUTICS, INC.

    Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (SUPPL-2) with active ingredient DAXIBOTULINUMTOXINA-LANM has changed to 'Approval' on 08/11/2023. Application Category: BLA, Application Number: 761127, Application Classification:

    8/14/23 4:38:56 AM ET
    $RVNC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DAXXIFY issued to REVANCE THERAPEUTICS, INC.

    Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (ORIG-1) with active ingredient daxibotulinumtoixnA-lanm has changed to 'Approval' on 09/07/2022. Application Category: BLA, Application Number: 761127, Application Classification:

    9/8/22 1:11:06 PM ET
    $RVNC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPE
    $COCH
    $CSTL
    $ENVB
    SEC Filings

    View All

    Tivic Health Systems Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/13/26 5:27:44 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by Gyre Therapeutics Inc.

    10-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

    3/13/26 4:31:11 PM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)

    3/12/26 6:31:12 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPE
    $COCH
    $CSTL
    $ENVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB

    Among all patients studied, 2.6% nodal positivity and 97.8% three-year recurrence-free survival (RFS) was observed in those predicted to have less than 5% risk of a positive sentinel lymph node (SLN) by DecisionDx-Melanoma's i31-SLNB Only 1.4% SLN positivity was observed in patients with T1b–T2a tumors predicted to have less than 5% risk The Company will host a webcast on Monday, March 23, at 4:30pm Eastern Time to discuss data from the publication FRIENDSWOOD, Texas, March 13, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of results from the largest prospectiv

    3/13/26 11:02:12 AM ET
    $CSTL
    Medical Specialities
    Health Care

    Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullgen to gain targeted protein degradation platform and pipeline; transaction anticipated to close in the second quarter of 2026 Alignment with China's Center for Drug Evaluation (CDE) on conditional approval filing and priority review eligibility for Hydronidone, subject to formal approval; New Drug Application (NDA) submission for conditional approval expected in the first half of 2026 Completed patient enrollment in the 52-week Phase 3 pirfenidone pneumoconiosis (PD) trial(272 patients acros

    3/12/26 6:00:00 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Envoy Medical Completes Enrollment of Pivotal Clinical Trial Evaluating First-Of-Its-Kind Fully Implanted Cochlear Implant

    First Cochlear Implant Company to Announce Completed Enrollment of a U.S. Pivotal Clinical Trial for a Fully Implanted Cochlear Implant seeking FDA ApprovalWhite Bear Lake, Minnesota--(Newsfile Corp. - March 11, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced completed enrollment of its pivotal clinical trial for the investigational fully implanted Acclaim® cochlear implant. With the successful implantation of the 56th and final patient, Envoy Medical is the first cochlear implant company to achieve full enrollment of a U.S. pivotal clinical trial to evaluate a fully implanted

    3/11/26 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $AMPE
    $COCH
    $CSTL
    $ENVB
    Leadership Updates

    Live Leadership Updates

    View All

    Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

    FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company's new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and other invited guests to commemorate the completion of the purpose-built facility. Local, state and national elected officials are expected to join the event, underscoring the significance of Castle's i

    3/3/26 4:30:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AMPE
    $COCH
    $CSTL
    $ENVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Castle Biosciences Inc.

    SC 13G/A - CASTLE BIOSCIENCES INC (0001447362) (Subject)

    11/14/24 4:40:39 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

    11/14/24 4:03:47 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ironwood Pharmaceuticals Inc.

    SC 13G - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

    11/14/24 3:31:33 PM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMPE
    $COCH
    $CSTL
    $ENVB
    Financials

    Live finance-specific insights

    View All

    Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullgen to gain targeted protein degradation platform and pipeline; transaction anticipated to close in the second quarter of 2026 Alignment with China's Center for Drug Evaluation (CDE) on conditional approval filing and priority review eligibility for Hydronidone, subject to formal approval; New Drug Application (NDA) submission for conditional approval expected in the first half of 2026 Completed patient enrollment in the 52-week Phase 3 pirfenidone pneumoconiosis (PD) trial(272 patients acros

    3/12/26 6:00:00 AM ET
    $GYRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

    2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025."We closed out an outstanding year with a strong fourth quarter, reflecting the strength of our innovative test portfolio, disciplined execution and the dedication of the entire Castle team who continue to d

    2/26/26 4:05:00 PM ET
    $CSTL
    Medical Specialities
    Health Care

    Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

    – LINZESS® (linaclotide) EUTRx demand growth of 11% for full year 2025 year-over-year – – 2025 Ironwood revenue of $296 million, GAAP net income of $24 million and adjusted EBITDA of $138 million – – Continue to expect full-year 2026 LINZESS® U.S. net sales of $1.125 to $1.175 billion; total revenues of $450 to $475 million and adjusted EBITDA of greater than $300 million – – Key elements of confirmatory Phase 3 clinical trial design of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) have been finalized with site initiations expected to begin in the second quarter of 2026 – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a biotechnology company developing and comm

    2/25/26 7:05:00 AM ET
    $IRWD
    Biotechnology: Pharmaceutical Preparations
    Health Care